The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer

European Journal of Surgical Oncology

Volumn 22, Issue 1, 1996, Pages 74-77

  Heiss, Markus M ^a   Babic, Rudolf ^b   Allgayer, Heike ^a   Gruetzner, Klaus U ^a   Jauch, Karl Walter ^a   Loehrs, Udo ^b   Schildberg, Friedrich W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Gastric cancer; Plasminogen activators; Prognosis; Tumour differentiation; uPA system

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN DEGRADATION; STOMACH CANCER; TUMOR DIFFERENTIATION;

EID: 0029925798     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(96)91649-2     Document Type: Article

References (20)

1. Schmitt M, Jaenicke F, Graeff H. Tumor-associated proteases. Fibrinolysis 1992; 6 (Suppl. 4): 3-26.
2. Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastas 1992; 10: 145-55.
3. Duffy MJ, Reilly D, O'Sullivan C, et al. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990; 50: 6827-9.
4. Jaenicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hoefler H, Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Tr 1993; 24: 195-208.
5. Takai S, Yamamura M, Tanaka K, et al. Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining. Int J Cancer 1991; 48: 20-7.
6. Sier CFM, Verspaget HW, Griffioen G, Ganesh S, Vloedgraven HJM, Lamers CBHW. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut 1993; 34: 80-5.
7. Heiss MM, Babic R, Allgayer H, et al. Prognostic value of new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. Surgical Forum, 80th Annual Clinical Congress (Vol. XLV) 1994: 482-5.
8. Nekarda H, Schmitt M, Ulm K, et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994; 54: 2900-7.
9. Morson BC, Dawson IMP, Day DW, Jass JR, Price AB, Williams GT. The Laurén Classification. In: Morrison, Dawson (eds) Gastrointestinal Pathology. Oxford, London, Edinburgh, Boston, Melbourne: Blackwell Scientific Publications, 1990: 151-2.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-81.
11. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 37: 1-39.
12. Cox DR. Regression models and life tables. J R Stat Soc(B) 1972; 34: 187-220.
13. Blasi F. Urokinase and urokinase receptor: a paracrine/ autocrine system regulating cell migration and invasiveness. BioEssays 1993; 15: 105-11.
14. Tryggvason K, Hoyhtya M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 1987; 907: 191-217.
15. Montesano R, Pepper MS, Moehlesteinlein U, Risan W, Wagner EF, Orci L. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T-oncogene. Cell 1990; 62: 435-45.
16. Babic R, Heiss MM, Mueller-Koelbl S. Tumorassoziierte Proteasen, ihre Rezeptoren und Inhibitoren. Immunhistochemische Untersuchung an Magenkarzinomen. Verh Dtsch Ges Path 1993; 77: 527.
17. Hermanek P. Clinical significance of histologic classification in accordance with Laurén as an addition to pTNM. Gastroenterology 1987; 22 (Suppl.): 31-2.
18. Schmitz-Mooremann P, Pohl C, Himmelmann GW, Neumann K. Morphological predictors of survival in advanced gastric carcinoma univariate and multivariate analysis. J Cancer Res Clin 1986; 112: 156-64.
19. Zilling TL, Willen R, Walther BS, Ranstam J. Prediction of survival in gastric carcinoma and a new histopathologic approach. Anticancer Res 1989; 9: 487-500.
20. Gabbert HE, Meier S, Gerharz CD, Hommels G. Tumor cell dissociation at the invasion front: a new prognostic parameter in gastric cancer patients. Int J Cancer 1992; 50: 202-7.